Clinical decision making requires evaluable disease status characteristics. Such variables are essential in both diagnosis and follow-up of small-cell lung cancer (SCLC) . Numerous qualitative and quantitative clinical and biochemical data are often available. so that it is difficult to select the most useful elements.
Various laboratory tests are widely used. as the initial step. in establishing the assessment of the disease (Cohen et al.. 1981; Souhami et al., 1985) . Two variables seem interesting in SCLC. The tumour marker serum neuron-specific enolase (S-NSE) has been found to be a potentially useful indicator of disease activity (Carney et al., 1982; Aroney et al., 1984; Adewole et al., 1987) . S-NSE is significantly related to extent of disease (Carney et al., 1982; Akoun, 1985; J0rgensen, 1989) , to response duration (Jorgensen et al., 1992) , and to prognosis (Jorgensen et al., 1988; Johnson et al., 1993) . The routine laboratory parameter serum lactate dehydrogenase (S-LDH) is in SCLC a strong prognostic factor (Cohen et al., 1981; Osterlind et al., 1983) , and an increase in S-LDH level is often a sign of progressing metastases, especially in the liver and bone marrow (Kn'stjansen et al., 1986; Sagman et al.. 1991 (CR, PR) followed by diagnosed progressive disease were eligible for the study.
S-NSE was analysed by the Pharmacia RIA method at the Diagnostic Development Unit, University of Leeds; the upper reference value was set to 12.5 jg 1'. S-LDH was analysed by our routine laboratory according to the Nordic recommendation (Scandinavian Society) and the upper reference value set to 450 U I-'.
S-NSE and S-LDH changes were correlated to disease status. The markers were assessed for their relative increase in relation to upper reference limits. The diagnostic efficacy of a marker to indicate CRTPR or PD was described by the receiver operating characteristics (ROC curves), and the diagnostic power function tested by the Mann-Whitney test (Siegel, 1988) .
Results
At inclusion 15 patients had LD and 12 ED. All but one were women. The median age was 58 years. All obtained objective remission. Eighty-five per cent of all pretreatment S-NSE values were increased compared with 37% of the S-LDH values (for further details see Table I ).
The marker values had normalised at re-evaluation except in three patients. One CR patient had a single increased S-NSE during follow-up, one PR patient experienced a steady S-NSE> 12.5 jig 1-' and S-LDH was marginally increased in one PR patient. During follow-up small oscillations were observed in both markers. Out of a total of 317 Br. J. Cancer (1994) . 70, [759] [760] [761] C Macmillan Press Ltd.. 1994 follow up samples S-NSE was > 12.5 iLg I' in five samples from four patients (median S-NSE 5.91 g I-', range 2.0-24.4 jig 1-') and S-LDH in 12 samples, from nine patients (median S-LDH 330 U 1-', range 132-746 U 1-'). For further details, see Table II .
All patients expenenced PD. Graphic analysis of each case showed exponential increments in S-NSE at the time of progression. PD was in 93% of patients associated with an increase in S-NSE (median 42.6ligl-', range 7.5-168.6 jug 1'). Two patients had S-NSE < 12.5 jLg 1' throughout the whole course, and S-LDH was at PD increased in only 56% (median 550 U 1. range 276-2,120 U 1-'). The marker increase preceded clinical progression by 20-50 days for S-NSE in ten patients and for S-LDH in five. A more precise assessment of lead time was impossible with a sample interval of 1 month. S-NSE increments at PD quantitatively exceeded the S-LDH changes. Highest S-NSE increment in PD was 12 times the upper reference limit compared with a maximum 4.7-fold increment in S-LDH (Figure 1) . Figure 2 shows the ROC curves for S-NSE and S-LDH. These curves illustrate the relative diagnostic accuracy of the tests in discriminating between CR or PR versus PD. Low values of reference limits resulted in higher sensitivity but lower specificity. A sensitivity of 0.93 and a specificity of 0.90 was achieved for a S-NSE cut-off point of 12.5jg 1-1. The applied S-LDH reference limit (450 U 1') resulted in a sensitivity of 0.68 and a specificity of 0. (Osterlind et al., 1983; Akoun et al., 1985; Splinter et al., 1987; J0rgensen et al., 1988) . Another important question is the ability of the marker to reflect disease status. Increased S-NSE was detected in 85% at inclusion and 93% at PD, while S-LDH had a disease correspondence of 37% at inclusion and 56% at PD. The low incidence of increased S-LDH values might be explained by the careful clinical follow-up of patients, resulting in an early detection of PD.
Both of these enzyme markers might be expected to carry information on disease progression. The disease relation of S-NSE is explained by its derivation from the tumour. S-LDH has been shown to be positively correlated with both liver and bone marrow metastases (Sagman et al., 1991) . Both markers are informative in PD and are significant prognostic factors in SCLC (J0rgensen et al., 1988) , encouraging the use of both markers in the management of SCLC. Our finding of an exponential rise in S-NSE at PD is in accordance with the study by Splinter et al. (1987) . In our investigation a rise in marker level was defined as stable if two or more sample results showed an identical tendency. During response we often found small oscillations below the reference limit in both S-NSE and S-LDH values, but we did not observe the high-amplitude S-NSE spikes of up to 35 jg 1' recorded by Muiller et al. (1992) . The signal changes relating to disease status were higher for S-NSE than for S-LDH. S-NSE thus provides a higher proportion of increased values in PD with a better signal-to-noise ratio than S-LDH. This prompts us to conclude that S-NSE should replace S-LDH as prognostic factor and disease activity monitor in SCLC.
